Shares of Adagio Therapeutics Inc. (NASDAQ:ADGI) traded at a new 52-week high today of $31.56. So far today approximately 137,000 shares have been exchanged, as compared to an average 30-day volume of 0,000 shares.
Adagio Therapeutics Inc. (NASDAQ:ADGI) is currently priced 43.4% above its average consensus analyst price target of $16.25.
Adagio Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s lead product candidate, ADG20 is developed for the treatment and prevention of coronavirus disease 2019, or COVID-19, the disease caused by the virus SARS-CoV-2 and its variants.
Adagio Therapeutics Inc. share prices have moved between a 52-week high of $31.56 and a 52-week low of $20.50 and are now trading 40% above that low price at $28.70 per share.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer